NexEos Bio Receives FDA Clearance for Phase II/III Trial of NTX-1024 in Rare Eye Disease
核心洞察
NexEos Bio (搜索) announced FDA clearance of its IND application to proceed with a Phase II/III trial of NTX-1024 for vernal keratoconjunctivitis (搜索) (VKC), a rare eosinophil-mediated eye disease.
The approval follows positive results from an open-label study in Mexico with 15 VKC patients showing significant improvements in symptoms and inflammation markers.
NTX-1024 would be the first ophthalmic therapeutic to neutralize eosinophil cationic protein (搜索), potentially offering a disease-modifying and steroid-sparing treatment option.
NexEos Bio (搜索) Vision Health has received FDA clearance to advance NTX-1024 (gleceparin sodium (搜索)) into a Phase II/III clinical trial for vernal keratoconjunctivitis (搜索) (VKC), marking a significant milestone for patients with this rare and vision-threatening eye disease. The FDA's clearance of the Investigational New Drug (IND) application paves the way for what could become the first therapeutic specifically targeting eosinophil cationic protein (搜索)-mediated inflammation in rare forms of allergic conjunctivitis (搜索).
Promising Early Clinical Results Drive FDA Decision
The FDA's approval follows encouraging data from an open-label, investigator-initiated study conducted in Mexico that enrolled 15 patients with mild to moderate VKC. Participants received NTX-1024 eye drops four times daily over a four-week treatment period, demonstrating significant improvements across multiple clinical measures.
Treatment with NTX-1024 led to substantial improvements in patient-reported symptoms, particularly itching and overall quality of life. Clinical assessments revealed reductions in key inflammation markers, including hyperemia and corneal fluorescein staining. The therapy was found to be safe and well-tolerated throughout the study period, representing the first clinical evaluation of NTX-1024 in VKC patients.
Addressing Critical Unmet Medical Need
VKC represents a rare, chronic, and vision-threatening ocular inflammatory disease that is predominantly eosinophil-mediated. The condition occurs when activated eosinophils release toxic granule proteins, including eosinophil major basic protein-1 (搜索) (eMBP1), causing damage to the ocular surface. While VKC primarily affects children, approximately 10% of cases persist into adulthood, and uncontrolled disease can result in severe ocular damage and permanent vision loss.
"Clearance of our IND application, which included data from our open-label investigator-initiated study in Mexico, is an important and meaningful step for the program," said Steve Tullman, CEO and Chairman of NexEos. "We are excited to advance clinical development of NTX-1024, which would be the first, ophthalmic therapeutic to neutralizes eosinophil cationic protein (搜索) to reduce inflammation in rare forms of Allergic Conjunctivitis (搜索) - Vernal Keratoconjunctivitis (搜索) (VKC) and Atopic Keratoconjunctivitis (搜索) (AKC)."
Novel Mechanism of Action
NTX-1024 represents a novel approach to treating eosinophil-mediated ocular inflammation through its unique mechanism of neutralizing eosinophil cationic proteins. This topical ophthalmic solution targets the underlying pathophysiology of VKC and atopic keratoconjunctivitis (搜索) (AKC), potentially offering both disease-modifying and steroid-sparing benefits.
The therapeutic has already achieved several regulatory milestones, including Orphan Drug Designation granted by the FDA on January 16, 2026, recognizing the significant unmet medical need in VKC treatment.
Clinical Development Timeline
The planned Phase II/III trial will be conducted as a single, randomized, double-masked, vehicle-controlled study to evaluate both the safety and efficacy of NTX-1024 ophthalmic solution in VKC patients. NexEos expects to initiate this pivotal trial by the second half of 2026, bringing the company closer to its objective of delivering a potential best-in-class therapeutic option for VKC patients.
Tullman emphasized the company's commitment to addressing unmet needs in eosinophil-related diseases, stating they are "on track to initiate our Phase II/III clinical trial by the second half of this year, taking us closer to our objective of delivering a best-in-class therapeutic option to patients with VKC."